Stephen T. Oh

9.2k citations

151 papers · 3.7k indexed · 2 hit papers · h-index 27

Impact in

Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments

Papers in

Genetics 123
- Myeloproliferative Neoplasms: Diagnosis and Treatment 120
- Hemoglobinopathies and Related Disorders 12
- Chronic Lymphocytic Leukemia Research 6
Hematology 104
- Chronic Myeloid Leukemia Treatments 59
- Acute Myeloid Leukemia Research 46

Co-authors: Jason Gotlib Laimonis A. Laimins Amy Zhou Olga Malkova Ruben A. Mesa Megan A. Cooper Todd A. Fehniger Rizwan Romee
Journals: Blood (56 papers)Journal of Clinical Oncology (10 papers)Leukemia (5 papers)Cancer Research (5 papers)Blood Advances (4 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Stephen T. Oh

142 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia 2016 · 660 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Science Translational Medicine
2013 New England Journal of Medicine

Peers

Countries citing papers authored by Stephen T. Oh

Since Specialization

Citations

This map shows the geographic impact of Stephen T. Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen T. Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen T. Oh more than expected).

Fields of papers citing papers by Stephen T. Oh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen T. Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen T. Oh. The network helps show where Stephen T. Oh may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephen T. Oh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen T. Oh Line = papers co-authored together Stephen T. Oh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	JAK inhibitor selection in challenging scenarios of myelofibrosis: a review Haematologica ·Pankit Vachhani, Ruben A. Mesa, John Mascarenhas, Raajit K. Rampal, Stephen T. Oh, Edmond. Auteur du texte Guérin, María Laura Fox, Francesca Palandri, Francesco Passamonti, Jean‐Jacques Kiladjian, Javier Conesa López, Claire Harrison, Prithviraj Bose	2025	0
2	SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms Cancer Immunology Research ·Melinda A. Biernacki, Haron Siddique, Kimberly A. Foster, Carrie Cummings, R W Galloway, Daria Gubachova, Jânia Perla Diógenes de Aquino, Mouloud El Hafidi, Victoria A. Green, Stephen T. Oh, Vivian G. Oehler, Derek L. Stirewalt, David Wu, H. Joachim Deeg, Sergei Doulatov, Marie Bleakley	2025	0
3	Pseudo‐lymphocytosis caused by circulating megakaryocyte fragments in a patient with post‐essential thrombocythemia myelofibrosis International Journal of Laboratory Hematology ·Camila dos Santos Bertoldi, John L. Frater, Lyudmila G. Egorova, Stephen T. Oh, Cara Lunn Shirai	2024	0
4	Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Clinical Cancer Research ·Duc Tran, J. Scott Beeler, Jie Liu, Ibrahim A. Alsayer, Jagmohan SinghBains, 靖司穐山, Michael H. Kramer, Armel L. Batchi‐Bouyou, Xiaoyu Zong, Matthew J. Walter, Fredy Randolfo Barahona Escoto, Sarantis Chlamydas, Francesca Ferraro, Stephen T. Oh, Daniel C. Link, Ben Busby, Yin Cao, Kelly L. Bolton	2024	3
5	Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib Clinical Lymphoma Myeloma & Leukemia ·Claire Harrison, Ruben A. Mesa, Moshe Talpaz, Jon Nevill, Aaron T. Gerds, Andrew C. Perkins, Yeow Tee Goh, María Laura Fox, Donal P. McLornan, Jeanne Palmer, Lynda Foltz, Alessandro M. Vannucchi, Steffen Koschmieder, Francesco Passamonti, Sung‐Eun Lee, S.N. Gordeev, Bryan Strouse, JJ Peña, Stephen T. Oh	2024	2
6	RSK1 dependency in FLT3-ITD acute myeloid leukemia Blood Cancer Journal ·Tim Kong, Angelo B. A. Laranjeira, Christopher T. Letson, Pil J. Yoo, Lebedeva Lyudmila, Aarthi Jayanthan, Gerrit Los, Sandra E. Dunn, Grant A. Challen, Stephen T. Oh	2024	2
7	Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis Blood Advances ·Stephen T. Oh, Ruben A. Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bart L. Scott, Jean‐Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah Buckley, Shanthakumar Tyavanagimatt, Bryan Harder, 刘曜国, Jennifer A. Smith, Adam R. Craig, John Mascarenhas, Srđan Verstovšek	2023	39
8	POSTER: MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1 Clinical Lymphoma Myeloma & Leukemia ·Vikas Gupta, Stephen T. Oh, Timothy Devos, Viviane Dubruille, John Catalano, SAKINAT OLUWABUKONLA FOLORUNSO, Pilar Giraldo, Hiroshi Kosugi, Tomasz Sacha, Jiří Mayer, Árpád Illés, Catherine Ellis, Zhaohui Wang, Jun Kawashima, Ruben A. Mesa	2023	1
9	Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) Blood ·Prithviraj Bose, Stephen T. Oh, Brian D. Modena, Anthony M. Hunter, Cem Akin, Mariana Castells, M.A. Manning, Richard Herrscher, Frank Siebenhaar, Daniel J. DeAngelo, Tracy I. George, Mituru Uyama, T Szczesnik, Maritta Perala, Hina Jolin, Rachael Easton, Lindsay Rein	2023	3
10	Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials HemaSphere ·Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srđan Verstovšek, Miklós Egyed, Uwe Platzbecker, Jiřı́ Mayer, Sebastian Grosicki, Árpád Illés, I. V. Dziublyk, Stephen T. Oh, Donal P. McLornan, Ilya Kirgner, Sung‐Soo Yoon, Claire Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben A. Mesa	2023	10
11	IMC-Denoise: a content aware denoising pipeline to enhance Imaging Mass Cytometry Nature Communications ·Eliashevich Vl, Karolyn A. Oetjen, Diane E. Bender, Marianna B. Ruzinova, Daniel A.C. Fisher, Kevin G. Shim, Russell K. Pachynski, W. Nathaniel Brennen, Stephen T. Oh, Daniel C. Link, Daniel L.J. Thorek	2023	29
12	Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis Leukemia ·Ruben A. Mesa, Claire Harrison, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean‐Jacques Kiladjian, Ewa Lech‐Marańda, Donal P. McLornan, Alessandro M. Vannucchi, Uwe Platzbecker, Mei Huang, Bryan Strouse, Barbara Klencke, Srđan Verstovšek	2022	40
13	Defining disease modification in myelofibrosis in the era of targeted therapy Cancer ·Naveen Pemmaraju, Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta, Jacqueline S. Garcia, Joseph M. Scandura, Stephen T. Oh, Francesco Passamonti, Konstanze Döhner, Adam J. Mead	2022	44
14	DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression Nature Cancer ·Tim Kong, Angelo B. A. Laranjeira, Kalyani Tukaram Bhandwalkar, Daniel A.C. Fisher, Pil J. Yoo, Владимир Бабич, Anthony Z. Wang, Marianna B. Ruzinova, Jared S. Fowles, Mary C. Fulbright, Tsuneo IWASAKI, Hamza Celik, Grant A. Challen, Sidong Huang, Stephen T. Oh	2022	25
15	Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry JCI Insight ·Luciano Galdieri, Arijita Jash, Olga Malkova, Diane D. Mao, Yan-Hong Cheng, Rached Omer Agwil, Amber Salter, Jian Campian, Kristen M. Naegle, Cameron Brennan, Hiroaki Wakimoto, Stephen T. Oh, Albert H. Kim, Milan G. Chheda	2021	20
16	Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry Blood ·Karolyn A. Oetjen, Lili Geng, Marianna B. Ruzinova, Stephen T. Oh, Daniel C. Link	2019	1
17	A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia Cancer Research ·David R. Spiciarich, Stephen T. Oh, Hossein Abedi Firouzjaee, A. Badowski, Michael J. Mauro, Omar Abdel‐Wahab, Richard D. Press, Rosa Viner, Sarah L. Thompson, Qiushi Chen, Parastoo Azadi, Carolyn R. Bertozzi, Julia E. Maxson	2018	16
18	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen Cancer Medicine ·Alaa M. Ali, O.N. Chalaya, Feng Gao, Geoffrey L. Uy, Amanda F. Cashen, Meagan A. Jacoby, Lukas D. Wartman, Armin Ghobadi, Iskra Pusic, Rizwan Romee, Todd A. Fehniger, Keith Stockerl‐Goldstein, Ravi Vij, Stephen T. Oh, Camille N. Abboud, Mark A. Schroeder, Peter Westervelt, John F. DiPersio, John S. Welch	2017	21
19	Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening Cancer Research ·Jeffrey Tyner, Hannah Kang, Armand Bankhead, Guang Fan, Luke B. Fletcher, Jade Bryant, Jason Glover, Bill H. Chang, Stephen E. Spurgeon, William H. Fleming, Tibor Kovacsovics, Jason Gotlib, Stephen T. Oh, Michael W. Deininger, C. Michel Zwaan, Monique L. den Boer, Marry M. van den Heuvel‐Eibrink, Thomas O’Hare, Brian Druker, Marc Loriaux	2012	100
20	Colchicine reverts cell shape but not collagen phenotypes in corneal endothelial cells modulated by polymorphonuclear leukocytes. PubMed ·EunDuck P. Kay, Stephen T. Oh	1987	2

About Stephen T. Oh

Stephen T. Oh is a scholar working on Genetics, Hematology, Rheumatology, Molecular Biology and Oncology, having authored 151 papers that have together received 3.7k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (120 papers), Chronic Myeloid Leukemia Treatments (59 papers), Acute Myeloid Leukemia Research (46 papers), Kruppel-like factors research (32 papers), Eosinophilic Disorders and Syndromes (31 papers), Hemoglobinopathies and Related Disorders (12 papers), Cytokine Signaling Pathways and Interactions (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). The work is most often cited by research in Genetics (1.6k citations), Hematology (1.6k citations), Immunology (1.0k citations), Rheumatology (564 citations) and Oncology (909 citations). Stephen T. Oh has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Jason Gotlib, Laimonis A. Laimins, Amy Zhou, Olga Malkova, Ruben A. Mesa, Megan A. Cooper, Todd A. Fehniger, Rizwan Romee, Liyang Yu and Sarah Willey. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Cancer Research and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact